Miracor Medical Systems, a Vienna, Austria-based medical device company, closed a €4.5m extension to its Series B financing.
Backers included new investors BioMedInvest and aws Gründerfonds and existing investors Earlybird Venture Capital, Delta Partners and SHS.
The company, which has raised over €16m in venture capital and another €8m in public funding, intends to use the funds to expand clinical trials and commercialize the PICSO® (Pressure-controlled Intermittent Coronary Sinus Occlusion) Impulse System, which is designed to treat acute ST-Segment Elevation Myocardial Infarction (STEMI) patients and less severe Non-ST-Segment Elevation Myocardial Infarction (‘NSTEMI’) patients by improving myocardial perfusion in complement with percutaneous coronary intervention (PCI).
Led by Ludwig Gold, CEO, Miracor is currently conducting several single- and multi-center clinical trials with up to 180 patients across Europe, to further demonstrate effectiveness of the PICSO Impulse System in improving myocardial perfusion in complement with percutaneous coronary intervention (PCI) in acute myocardial infarction patients.
FinSMEs
08/01/2015